Treatment of chronic osteomyelitis often leaves a large critical defect which requires a bone void filler, yet current void fillers are inadequate because of donor site morbidity, expense or their propensity to encourage infection, ” said Dr. Mathias P.G. Bostrom, Orthopedic Surgeon at Hospital for Special Surgery (HSS) in New York and co-author of the study.  “This study showed CERAMENTT’G to be effective in decreasing the rate of infection and simultaneously increasing new bone growth, two essential functions for successful management of osteomyelitis.”

CERAMENTT’G is an injectable, resorbable bone graft substitute designed to fill bone gaps and voids and to augment hardware and bone fractures during surgical procedures.  CERAMENTT has been shown to remodel into healthy native bone within 6 to 12 months.  The efficient elution profile and the focused local delivery of gentamicin obtained with CERAMENTT’G is intended to prevent colonization of sensitive microorganisms, thereby protecting the bone healing, particularly in challenging cases of deep bone infection.

 “This is the first animal study to evaluate CERAMENTT’G in a septic condition and we were very pleased with the results,” said Lloyd Diamond, CEO of BONESUPPORT.  “Clinical investigation has always been the foundation from which we have built a robust portfolio and it will continue to play an important role as we expand into new markets and new indications with our proprietary drug-delivery platform.”

Osteomyelitis, or Bone Infection is a $1.7 billion market where prolonged, long-term antibiotic therapy, multiple surgical interventions and the threat of amputation are the current standard of care. Rising prosthetic infections, diabetic ulcers, war injuries, sports injuries, and an increasing resistance to antibiotics contribute to this growing condition.


BONESUPPORT is an emerging leader of injectable bone graft substitutes for orthopedics, and trauma focusing on bone infection, instrument augmentation and spinal applications. CERAMENTT is an injectable, synthetic bone substitute that mimics the properties of cancellous bone, allows for controlled resorption to support future bone ingrowth and is injectable under local anesthesia for minimally invasive surgery. CERAMENTT’G and CERAMENTT’V are the first CE-marked injectable antibiotic eluting ceramic bone graft substitutes indicated to promote and protect bone healing in the management of osteomyelitis, (bone infections). CERAMENT’s unique biologic properties deliver a consistent, pre-packed and ready-to-use formulation to facilitate optimal delivery. CERAMENTT’G and CERAMENTT’V are not available in the United States.

CERAMENTT is a fully developed product platform that is commercially available in the U.S., Europe, SE Asia and the Middle East. CERAMENTT is revolutionizing the treatment of fragility and other fractures caused by disease and trauma. Scientific research of CERAMENT spans more than eleven years. Over forty-five pre-clinical, clinical and animal studies have been conducted and more than 10,000 patients have been treated with CERAMENT.  The company was founded in 1999 and is based in Lund, Sweden with subsidiary locations in the US and Germany. To learn more about BONESUPPORT please visit www.bonesupport.com.

Press Inquiries:
Offer Nonhoff
Chief Financial Officer
Phone +46 46 286 53 60
PR 0425-01 en


90 million to 18 Talented Researchers
19. October 2020
Søren Dinesen Lumdbeckfonden
Psychiatry research leads to prestigious science prize
13. October 2020
Christian Sandøe Musaeus Lundbeckfonden
Concentrating on Dementia
13. October 2020


Lundbeckfonden Ventures

Lundbeckfonden Emerge